Multishell Colloidosome Platform with Sequential Gastrointestinal Resistance for On‐Demand Probiotic Delivery
Advanced Healthcare Materials · 2023
DOI: 10.1002/adhm.202202954 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2023. Verfasst von Xin Xie und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences and Engineering, Southwest Jiaotong University, Chengdu, Sichuan, 610031, P. R. China. Hauptthemen laut MEDLINE: Colitis, Probiotics. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, Sichuan Province Science and Technology Support Program.
Abstract (Originalsprache)
Probiotic‐based oral therapy can potentially prevent and treat diseases by regulating the balance of intestinal flora. However, significant loss of viability and bioactivity of probiotics before reaching the colon results in low delivery efficiency and therapeutic effects, which limits their clinical applications. Here, this work proposes a multishell colloidosome (MSC) platform with sequential gastrointestinal resistance for on‐demand probiotic delivery based on biomimetic mineralization and microfluidic technology. Notably, the viability of the decorated probiotics increases 280‐fold compared to that of free bacteria during preservation. Because of the sequential gastrointestinal resistance of MSC, encapsulated probiotics exhibit high viability (61%) under continuous exposure to extreme acidity, bile salt erosion, and enzymatic action, whereas free bacteria have a viability of 0%. Moreover, in vitro and in vivo studies reveal that MSC mainly releases probiotics in the colon and improves colonic colonization by probiotics to maintain the integrity of the intestinal barrier and regulate the balance of intestinal flora. Consequently, MSC significantly improves the therapeutic effect on colitis in mice. The MSC platform provides a promising delivery strategy to enhance the efficacy of orally administered probiotics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Life Sciences and Engineering, Southwest Jiaotong University, Chengdu, Sichuan, 610031, P. R. China.
ORCID-Profile: Tao Meng
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
- Sichuan Province Science and Technology Support Program
Zitieren
APA
Xie, X., Li, Q., Jia, L., Yuan, H., Guo, T., & Meng, T. (2023). Multishell Colloidosome Platform with Sequential Gastrointestinal Resistance for On‐Demand Probiotic Delivery. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202202954
Vancouver
Xie X, Li Q, Jia L, Yuan H, Guo T, Meng T. Multishell Colloidosome Platform with Sequential Gastrointestinal Resistance for On‐Demand Probiotic Delivery. Advanced Healthcare Materials. 2023. doi:10.1002/adhm.202202954
BibTeX
@article{Xie2023,
author = {Xie, Xin and Li, Qinyuan and Jia, Lufan and Yuan, Hao and Guo, Ting and Meng, Tao},
title = {Multishell Colloidosome Platform with Sequential Gastrointestinal Resistance for On‐Demand Probiotic Delivery},
journal = {Advanced Healthcare Materials},
year = {2023},
doi = {10.1002/adhm.202202954}
}
EUVIMED